Abstract
Background Recent research has shown that the G protein-coupled receptor 110 (GPR110) is an oncogene. The evidence mainly based on high expression of GPR110 in numerous cancer types; and knockdown GPR110 can reduced the cell migration, invasion, and proliferation. GPR110 is, however, mostly expressed in the liver of healthy individuals. The function of GPR110 in liver has not been revealed. Interestingly, expression level of hepatic GPR110 is dramatically decreased in obese subjects. Here, we examined whether GPR110 has a role in liver metabolism.
Methods We used recombinant adeno-associated virus-mediated gene delivery system and antisense oligonucleotide to manipulate the hepatic GPR110 expression level in diet-induced obese mice to investigate the role of GPR110 in hepatic steatosis. The clinical relevance was examined using transcriptome profiling and archived biopsy specimens of liver tissues from non-alcoholic fatty liver disease (NAFLD) patients with different degree of fatty liver.
Results The expression of GPR110 in the liver was directly correlated to fat content in the livers of both obese mice and NAFLD patients. Stearoyl-coA desaturase 1 (SCD1), a crucial enzyme in hepatic de novo lipogenesis, was identified as a downstream target of GPR110 by RNA-sequencing analysis. Treatment with the liver-specific SCD1 inhibitor MK8245 and specific shRNAs against SCD1 in primary hepatocytes improved the hepatic steatosis of GPR110-overexpressing mice and lipid profile of hepatocytes, respectively.
Conclusions These results indicate GPR110 regulates hepatic lipid metabolism through controlling the expression of SCD1. Down-regulation of GPR110 expression can potentially serve as a protective mechanism to stop the over-accumulation of fat in the liver in obese subjects. Overall, our findings not only reveal a new mechanism regulation the progression of NALFD, but also proposed a novel therapeutic approach to combat NAFLD by targeting GPR110.
Fundings This work was supported in part by National Natural Science Foundation of China 81870586 (CMW), 82270941 and 81974117 (JS), Area of Excellence AoE/M-707/18 (AX and CMW), and General Research Fund 15101520 (CMW).
Highlights
GPR110 regulates hepatic lipid metabolism.
High level of hepatic GPR110 aggravates the progression of NAFLD by inducing SCD1 expression.
Reduction in hepatic GPR110 is required to alleviate the progression of NAFLD.
Targeting hepatic GPR110 improves hepatic steatosis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by National Natural Science Foundation of China (81870586), Area of Excellence (AoE/M-707/18), and General Research Fund (15101520) to C.M.W., and National Natural Science Foundation of China (82270941, 81974117) to S.J.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All animal procedures were approved by the Animal Subjects Ethics Sub-Committee of the Hong Kong Polytechnic University and were conducted in accordance with the guidelines of the Centralized Animals Facilities (19-20/78-HTI-R-OTHERS). The human study is approved by the Human Ethics Committee of Zhujiang Hospital, Southern Medical University, Guangzhou, China (Number: 2019-KY-097-01).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Competing Interests: None.
Abbreviations: ADGRE1, adhesion G Protein-Coupled Receptor E1; ADV, adenovirus; ALT, alanine aminotransferase; ASO, antisense oligonucleotide; AST, aspartate aminotransferase; cDNA, complementary DNA; CHO, cholesterol; DIO, diet-induced obesity; FGF21, fibroblast growth factor 21; GPCR, G protein coupled receptor; GPR110, G-protein coupled receptor 110; EWAT, epididymal white tissue; FFA, free fatty acids; GFP, green fluorescent protein; HCC, hepatocellular carcinoma; HDL, high-density lipoprotein; H&E, hematoxylin and eosin; HFD, high-fat diet; HOMA-IR, Homeostatic Model Assessment of Insulin Resistance; KEGG, Kyoto Encyclopedia of Genes and Genomes; LDL, low-density lipoprotein; MUFA, monounsaturated fatty acids; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; NCD, non-communicable diseases; NPC, Non-parenchymal cells; ORO, Oil Red O; SCD1, stearoyl-CoA desaturase-1; rAAV, recombinant adeno-associated virus; STC, standard chow diet; TG triglyceride.
Data Availability
All data generated or analysed during this study are included in the manuscript and supporting file as Supplementary Table 3.
